You'll find a wide range of articles and resources on conditions and diseases
A UCLA study has identified a way to turn off a key signaling pathway involved in physiological processes that can also stimulate the development of cancer and other diseases.
A UCLA study has identified a way to turn off a key signaling pathway involved in physiological processes that can also stimulate the development of cancer and other diseases. The findings may lead to new treatments and targeted drugs using this approach.
Human Genome Sciences (HGS) Inc announced early results in BLISS-52 trial using BENLYSTA (belimumab, formerly LymphoStat-B). The results have left them blissful as the study results showed patients who took Benlysta demonstrated a statistically significant improvement in the symptoms of their disease compared with those taking a placebo.
Human Genome Sciences (HGS) Inc announced early results in BLISS-52 trial using BENLYSTA (belimumab, formerly LymphoStat-B). The results have left them blissful as the study results showed patients who took Benlysta demonstrated a statistically significant improvement in the symptoms of their disease compared with those taking a placebo.
